What’s Propelling Proteostasis Therapeutics, Inc. (PTI) to Decline So Much?

June 7, 2018 - By Jason Grubb

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Logo

The stock of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) is a huge mover today! The stock decreased 38.16% or $1.87 during the last trading session, reaching $3.03. About 6.23M shares traded or 201.78% up from the average. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has risen 10.56% since June 8, 2017 and is uptrending. It has underperformed by 2.01% the S&P500.
The move comes after 5 months negative chart setup for the $109.33 million company. It was reported on Jun, 8 by Barchart.com. We have $2.88 PT which if reached, will make NASDAQ:PTI worth $5.47M less.

More notable recent Proteostasis Therapeutics, Inc. (NASDAQ:PTI) news were published by: Benzinga.com which released: “8 Biggest Price Target Changes For Thursday” on June 07, 2018, also Streetinsider.com with their article: “Pre-Open Movers 06/07: (AVHI) (CONN) (FIVE) Higher; (MDXG) (PTI) (REVG) Lower (more…)” published on June 07, 2018, Benzinga.com published: “9 Stocks Moving In Wednesday’s After-Hours Session” on June 06, 2018. More interesting news about Proteostasis Therapeutics, Inc. (NASDAQ:PTI) were released by: Benzinga.com and their article: “27 Stocks Moving In Thursday’s Pre-Market Session” published on June 07, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Afternoon Market Update: NASDAQ Down Over 1%; AV Homes Shares Spike Higher” with publication date: June 07, 2018.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. The company has market cap of $109.33 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. It currently has negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: